Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVXL-0301
- Development stage
- Preclinical
- Lead developer
- CleveXel Pharma
- Modality
- Peptides
01
Overview
CVXL-0301 is a peptide-based therapeutic candidate currently in preclinical development by CleveXel Pharma. As of the available pipeline information, the specific biological target and primary therapeutic indication for CVXL-0301 have not been publicly disclosed. CleveXel Pharma, a French pharmaceutical company specializing in drug development across central nervous system (CNS) disorders, oncology, and immuno-inflammation, is advancing the asset through early-stage studies. The compound is part of a broader portfolio of assets developed by the company, which often focuses on neurodegenerative diseases and cancer.
Beyond the preview
Go deeper on CVXL-0301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVXL-0301.